Benjamin F. Edwards & Company, Inc. Crispr Therapeutics Ag Transaction History
Benjamin F. Edwards & Company, Inc.
- $5.69 Billion
- Q2 2024
A detailed history of Benjamin F. Edwards & Company, Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Benjamin F. Edwards & Company, Inc. holds 34,081 shares of CRSP stock, worth $2.11 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
34,081
Previous 663
5040.42%
Holding current value
$2.11 Million
Previous $45,000
3988.89%
% of portfolio
0.03%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding CRSP
# of Institutions
541Shares Held
68.5MCall Options Held
3.67MPut Options Held
2.25M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl10.2MShares$631 Million4.09% of portfolio
-
Capital International Investors Los Angeles, CA5.59MShares$347 Million0.05% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.68MShares$228 Million0.11% of portfolio
-
State Street Corp Boston, MA3.27MShares$203 Million0.01% of portfolio
-
Ubs Group Ag2.84MShares$176 Million0.02% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $4.83B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....